NCT07104812View on ClinicalTrials.gov

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions

Mild Autonomous Cortisol SecretionAutonomous Cortisol Secretion (ACS)

Interventions

DRUG

Osilodrostat 1 MG

Osilodrostat 1 mg administered between noon and 6 pm daily, for 4 weeks

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Recordati Rare Diseases

INDUSTRY

lead

Mayo Clinic

OTHER